News Image

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

Provided By GlobeNewswire

Last update: May 20, 2024

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.

Read more at globenewswire.com
Follow ChartMill for more